港媒：国内外企业争抢中国市场，减肥药价格暴跌

Group 1 - The article discusses the intense competition among domestic and international pharmaceutical companies in China's weight loss drug market, driven by a significant increase in obesity issues and a drastic price reduction of up to 80% for weight loss medications [1] - Major pharmaceutical giants like Novo Nordisk and Eli Lilly currently dominate the market, but the landscape is expected to change with the anticipated approval of their weight loss drugs in China in 2024 [1] - The price war began in late December, with reports of a 50% price drop for the weight loss drug semaglutide in procurement platforms in Yunnan and Sichuan provinces, highlighting the importance of maintaining market share over high profit margins [1] Group 2 - Chinese pharmaceutical companies are seizing the opportunity presented by the upcoming "patent cliff" and increasing demand, with over 60 related new drugs currently in phase III clinical trials that aim to compete with semaglutide and tirzepatide [2] - A Chinese weight loss drug, MSDT (Masitide), developed by Innovent Biologics, has also followed suit by reducing its price in early January to capture a larger share of the low penetration GLP-1 weight loss drug market in China [2] - The market for weight loss drugs in China is projected to become increasingly consumer-focused, potentially turning into a game centered around entertainment and aesthetics [2]